Home＞BUSINESS
Mochida to Market Janssen’s Anticancer Agent Doxil in Japan(Nov.22.2017)
Mochida Pharmaceutical said on November 20 that it has entered into an agreement with Janssen Pharmaceutical for the marketing of the partner’s anticancer agent Doxil Injection 20 mg (doxorubicin) in Japan. Under the pact, Mochida will be responsible for the information provisioning to medical institutions and the distribution of the product from January 2018 ...
(LOG IN FOR FULL STORY)
-
-
Lilly Japan Marks Opening of New Kobe Headquarters
Jul.17
- Taiho Exercises Option to Gain Asian Rights to Arcus’ I/O Candidate Jul.17
- Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo Jul.17
- As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll Jul.13
- Ninlaro Hits Primary Endpoint in Post-Transplant Multiple Myeloma: Takeda Jul.13
- Lilly Japan Marks Opening of New Kobe Headquarters(Jul.17)
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27(Jul.17)
- Taiho Exercises Option to Gain Asian Rights to Arcus’ I/O Candidate(Jul.17)
- Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo(Jul.17)
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices(Jul.17)
